Jürgen Germann, Robert S. C. Amaral, Jennifer Tomaszczyk, Kazuaki Yamamoto, Gavin J. B. Elias, Flavia Venetucci Gouveia, Anna Vasilevskaya, Foad Taghdiri, Gabriel A. Devenyi, Tejas Sankar, Jeannie-Marie Leoutsakos, Cynthia A. Munro, Paul B. Rosenberg, Constantine G. Lyketsos, Esther S. Oh, William S. Anderson, Zoltan Mari, Lisa Fosdick, Kristen E. Drake, Steven D. Targum, Jo Cara Pendergrass, Anna Burke, Stephen Salloway, Wael F. Asaad, Francisco A. Ponce, Marwan Sabbagh, David A. Wolk, Gordon Baltuch, Michael S. Okun, Kelly D. Foote, Peter Giacobbe, Mary Pat McAndrews, David F. Tang-Wai, Gwenn S. Smith, M. Carmela Tartaglia, M. Mallar Chakravarty, Andres M. Lozano, for the Alzheimer's Disease Neuroimaging Initiative
{"title":"阿尔茨海默病与穹窿深部脑刺激相关的生物标志物变化","authors":"Jürgen Germann, Robert S. C. Amaral, Jennifer Tomaszczyk, Kazuaki Yamamoto, Gavin J. B. Elias, Flavia Venetucci Gouveia, Anna Vasilevskaya, Foad Taghdiri, Gabriel A. Devenyi, Tejas Sankar, Jeannie-Marie Leoutsakos, Cynthia A. Munro, Paul B. Rosenberg, Constantine G. Lyketsos, Esther S. Oh, William S. Anderson, Zoltan Mari, Lisa Fosdick, Kristen E. Drake, Steven D. Targum, Jo Cara Pendergrass, Anna Burke, Stephen Salloway, Wael F. Asaad, Francisco A. Ponce, Marwan Sabbagh, David A. Wolk, Gordon Baltuch, Michael S. Okun, Kelly D. Foote, Peter Giacobbe, Mary Pat McAndrews, David F. Tang-Wai, Gwenn S. Smith, M. Carmela Tartaglia, M. Mallar Chakravarty, Andres M. Lozano, for the Alzheimer's Disease Neuroimaging Initiative","doi":"10.1002/alz.70394","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> INTRODUCTION</h3>\n \n <p>Deep brain stimulation of the fornix (fx-DBS) is being investigated for treatment of Alzheimer's disease (AD). The therapy aims at alleviating memory and cognitive circuit dysfunction. In preclinical models of AD, electrical stimulation of the memory circuit has demonstrated a possible disease-modifying potential. Here we examined changes resulting from fx-DBS in hippocampal atrophy and amyloid accumulation in AD patients with fx-DBS.</p>\n </section>\n \n <section>\n \n <h3> METHODS</h3>\n \n <p>Repeated magnetic resonance imaging and positron emission tomography (PET) images acquired over the course of 12 months were used to assess changes in hippocampal volume in 36 ADvance trial patients compared to 40 matched untreated AD patients from the Alzheimer's Disease Neuroimaging Initiative, and in 10 separate patients with repeated flutemetamol PET and cerebrospinal fluid (CSF) markers.</p>\n </section>\n \n <section>\n \n <h3> RESULTS</h3>\n \n <p>We observed a reduction of hippocampal atrophy and amyloid beta (Aβ) PET binding, and an increase in the CSF Aβ/total-tau ratio in DBS patients.</p>\n </section>\n \n <section>\n \n <h3> DISCUSSION</h3>\n \n <p>These findings highlight the potential of fornix deep brain stimulation to modify AD biomarkers and possibly progression in some patients.</p>\n </section>\n \n <section>\n \n <h3> Highlights</h3>\n \n <div>\n <ul>\n \n <li>Fornix deep brain stimulation (fx-DBS) is being investigated to treat Alzheimer's disease (AD).</li>\n \n <li>Results show that fx-DBS modifies imaging and cerebrospinal fluid (CSF) markers.</li>\n \n <li>It reduces hippocampal atrophy and increases the amyloid beta/total-tau CSF ratio.</li>\n \n <li>These findings highlight the potential of fx-DBS to modify AD.</li>\n </ul>\n </div>\n </section>\n </div>","PeriodicalId":7471,"journal":{"name":"Alzheimer's & Dementia","volume":"21 6","pages":""},"PeriodicalIF":11.1000,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/alz.70394","citationCount":"0","resultStr":"{\"title\":\"Biomarker changes associated with fornix deep brain stimulation in Alzheimer's disease\",\"authors\":\"Jürgen Germann, Robert S. C. Amaral, Jennifer Tomaszczyk, Kazuaki Yamamoto, Gavin J. B. Elias, Flavia Venetucci Gouveia, Anna Vasilevskaya, Foad Taghdiri, Gabriel A. Devenyi, Tejas Sankar, Jeannie-Marie Leoutsakos, Cynthia A. Munro, Paul B. Rosenberg, Constantine G. Lyketsos, Esther S. Oh, William S. Anderson, Zoltan Mari, Lisa Fosdick, Kristen E. Drake, Steven D. Targum, Jo Cara Pendergrass, Anna Burke, Stephen Salloway, Wael F. Asaad, Francisco A. Ponce, Marwan Sabbagh, David A. Wolk, Gordon Baltuch, Michael S. Okun, Kelly D. Foote, Peter Giacobbe, Mary Pat McAndrews, David F. Tang-Wai, Gwenn S. Smith, M. Carmela Tartaglia, M. Mallar Chakravarty, Andres M. Lozano, for the Alzheimer's Disease Neuroimaging Initiative\",\"doi\":\"10.1002/alz.70394\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> INTRODUCTION</h3>\\n \\n <p>Deep brain stimulation of the fornix (fx-DBS) is being investigated for treatment of Alzheimer's disease (AD). The therapy aims at alleviating memory and cognitive circuit dysfunction. In preclinical models of AD, electrical stimulation of the memory circuit has demonstrated a possible disease-modifying potential. Here we examined changes resulting from fx-DBS in hippocampal atrophy and amyloid accumulation in AD patients with fx-DBS.</p>\\n </section>\\n \\n <section>\\n \\n <h3> METHODS</h3>\\n \\n <p>Repeated magnetic resonance imaging and positron emission tomography (PET) images acquired over the course of 12 months were used to assess changes in hippocampal volume in 36 ADvance trial patients compared to 40 matched untreated AD patients from the Alzheimer's Disease Neuroimaging Initiative, and in 10 separate patients with repeated flutemetamol PET and cerebrospinal fluid (CSF) markers.</p>\\n </section>\\n \\n <section>\\n \\n <h3> RESULTS</h3>\\n \\n <p>We observed a reduction of hippocampal atrophy and amyloid beta (Aβ) PET binding, and an increase in the CSF Aβ/total-tau ratio in DBS patients.</p>\\n </section>\\n \\n <section>\\n \\n <h3> DISCUSSION</h3>\\n \\n <p>These findings highlight the potential of fornix deep brain stimulation to modify AD biomarkers and possibly progression in some patients.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Highlights</h3>\\n \\n <div>\\n <ul>\\n \\n <li>Fornix deep brain stimulation (fx-DBS) is being investigated to treat Alzheimer's disease (AD).</li>\\n \\n <li>Results show that fx-DBS modifies imaging and cerebrospinal fluid (CSF) markers.</li>\\n \\n <li>It reduces hippocampal atrophy and increases the amyloid beta/total-tau CSF ratio.</li>\\n \\n <li>These findings highlight the potential of fx-DBS to modify AD.</li>\\n </ul>\\n </div>\\n </section>\\n </div>\",\"PeriodicalId\":7471,\"journal\":{\"name\":\"Alzheimer's & Dementia\",\"volume\":\"21 6\",\"pages\":\"\"},\"PeriodicalIF\":11.1000,\"publicationDate\":\"2025-06-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/alz.70394\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Alzheimer's & Dementia\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/alz.70394\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alzheimer's & Dementia","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/alz.70394","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
摘要
穹窿深部脑刺激（fx-DBS）正在被研究用于治疗阿尔茨海默病（AD）。该疗法旨在缓解记忆和认知回路功能障碍。在阿尔茨海默病的临床前模型中，电刺激记忆回路已经证明了一种可能的疾病改善潜力。在这里，我们研究了固定dbs对AD患者海马萎缩和淀粉样蛋白积累的影响。方法：在12个月的时间里获得重复磁共振成像和正电子发射断层扫描（PET）图像，用于评估36名ADvance试验患者的海马体积变化，与之相比，来自阿尔茨海默病神经影像学倡议的40名匹配的未治疗AD患者。以及10例重复氟替他莫PET和脑脊液（CSF）标记物的患者。结果：我们观察到DBS患者海马萎缩和淀粉样蛋白β (a β) PET结合减少，脑脊液a β/总tau比值增加。这些发现强调了穹窿深部脑刺激可能改变AD生物标志物，并可能在一些患者中发生进展。穹窿深部脑刺激（fix - dbs）正在被研究用于治疗阿尔茨海默病（AD）。结果显示，固定dbs改变了影像学和脑脊液（CSF）标志物。它减少海马萎缩，增加淀粉样蛋白/总tau脑脊液比率。这些发现突出了fix - dbs治疗AD的潜力。
Biomarker changes associated with fornix deep brain stimulation in Alzheimer's disease
INTRODUCTION
Deep brain stimulation of the fornix (fx-DBS) is being investigated for treatment of Alzheimer's disease (AD). The therapy aims at alleviating memory and cognitive circuit dysfunction. In preclinical models of AD, electrical stimulation of the memory circuit has demonstrated a possible disease-modifying potential. Here we examined changes resulting from fx-DBS in hippocampal atrophy and amyloid accumulation in AD patients with fx-DBS.
METHODS
Repeated magnetic resonance imaging and positron emission tomography (PET) images acquired over the course of 12 months were used to assess changes in hippocampal volume in 36 ADvance trial patients compared to 40 matched untreated AD patients from the Alzheimer's Disease Neuroimaging Initiative, and in 10 separate patients with repeated flutemetamol PET and cerebrospinal fluid (CSF) markers.
RESULTS
We observed a reduction of hippocampal atrophy and amyloid beta (Aβ) PET binding, and an increase in the CSF Aβ/total-tau ratio in DBS patients.
DISCUSSION
These findings highlight the potential of fornix deep brain stimulation to modify AD biomarkers and possibly progression in some patients.
Highlights
Fornix deep brain stimulation (fx-DBS) is being investigated to treat Alzheimer's disease (AD).
Results show that fx-DBS modifies imaging and cerebrospinal fluid (CSF) markers.
It reduces hippocampal atrophy and increases the amyloid beta/total-tau CSF ratio.
These findings highlight the potential of fx-DBS to modify AD.
期刊介绍：
Alzheimer's & Dementia is a peer-reviewed journal that aims to bridge knowledge gaps in dementia research by covering the entire spectrum, from basic science to clinical trials to social and behavioral investigations. It provides a platform for rapid communication of new findings and ideas, optimal translation of research into practical applications, increasing knowledge across diverse disciplines for early detection, diagnosis, and intervention, and identifying promising new research directions. In July 2008, Alzheimer's & Dementia was accepted for indexing by MEDLINE, recognizing its scientific merit and contribution to Alzheimer's research.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
